Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Yihao Liu, Qin Zeng, Caiguanxi Deng, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

T Cell Responses to SARS-CoV-2
Alessandro Sette, John Sidney, Shane Crotty
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 343-373
Closed Access | Times Cited: 126
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Qiaoli Peng, Runhong Zhou, Yuewen Wang, et al.
EBioMedicine (2022) Vol. 77, pp. 103904-103904
Open Access | Times Cited: 114
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 92
Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death
Zhuoying Huang, Shuangfei Xu, Jiechen Liu, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 83
A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
Joey Ming Er Lim, Shou Kit Hang, Smrithi Hariharaputran, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100793-100793
Open Access | Times Cited: 60
Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study
Jingwen Ai, Yi Zhang, Haocheng Zhang, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 639-647
Open Access | Times Cited: 41
Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
Yubin Liu, Ziyi Wang, Xinyu Zhuang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 33
Spleen fibroblastic reticular cell-derived acetylcholine promotes lipid metabolism to drive autoreactive B cell responses
Qin Zeng, Shuyi Wang, Mengyuan Li, et al.
Cell Metabolism (2023) Vol. 35, Iss. 5, pp. 837-854.e8
Closed Access | Times Cited: 30
In Situ Polymerization-Mediated Antigen Presentation
Chao Pan, Lu Wang, Mengmeng Zhang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 24, pp. 13261-13272
Closed Access | Times Cited: 29
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine
Koichi Furukawa, Lidya Handayani Tjan, Yukiya Kurahashi, et al.
JAMA Network Open (2022) Vol. 5, Iss. 5, pp. e2210780-e2210780
Open Access | Times Cited: 37
Is There Less Alteration of Smell Sensation in Patients With Omicron SARS-CoV-2 Variant Infection?
Juan José Rodríguez‐Sevilla, Roberto Güerri-Fernádez, B. Bertrán Recasens
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 35
Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19
Wei Zhao, Weixin Chen, Juan Li, et al.
mBio (2022) Vol. 13, Iss. 3
Open Access | Times Cited: 32
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Jiaying Shen, Junyan Fan, Yue Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates
Ruth Hunegnaw, Anna N. Honko, Lingshu Wang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 675
Closed Access | Times Cited: 27
Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
Nungruthai Suntronwong, Sitthichai Kanokudom, Chompoonut Auphimai, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 12, pp. 5713-5722
Open Access | Times Cited: 26
A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
Ji Wang, Caiguangxi Deng, Ming Liu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 26
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
Alessandra Aiello, Andrea Coppola, Serena Ruggieri, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 94, Iss. 4, pp. 290-299
Open Access | Times Cited: 26
A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants
Rui Wang, Hongpeng Huang, Chulin Yu, et al.
Science China Life Sciences (2022) Vol. 66, Iss. 8, pp. 1818-1830
Open Access | Times Cited: 26
Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals
Eustache Paramithiotis, Scott Sugden, Eszter Papp, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside
Justin Laracy, Mini Kamboj, Santosha A. Vardhana
Current Opinion in Infectious Diseases (2022) Vol. 35, Iss. 4, pp. 271-279
Open Access | Times Cited: 25
B cells: The many facets of B cells in allergic diseases
Pattraporn Satitsuksanoa, Sayuri Iwasaki, Jolien Boersma, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 3, pp. 567-581
Closed Access | Times Cited: 16
Application of Traditional Vaccine Development Strategies to SARS-CoV-2
Halie M. Rando, Ronan Lordan, Alexandra Lee, et al.
mSystems (2023) Vol. 8, Iss. 2
Open Access | Times Cited: 14
Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing
Renyang Tong, Lingjie Luo, Yichao Zhao, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 14
SARS-CoV-2 spike-specific TFH cells exhibit unique responses in infected and vaccinated individuals
Rongzhang He, Xingyu Zheng, Jian Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 14
Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
Paul Naaber, Liina Tserel, Kadri Kangro, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 8, pp. 100716-100716
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top